Call it what you want — disruption, strong-arming, jawboning, dealmaking — but one thing is undeniable: Donald Trump has taken a sledgehammer to one of the biggest rackets in America — middleman markups of prescription drugs.
And the drive-by cable news legacy media? Silent.
Not a whisper about one of the most tangible, kitchen-table, paycheck-saving wins of Trump’s second term. Because it doesn’t fit the narrative. It doesn’t feed the outrage machine.
Let’s talk reality. Let’s talk numbers. Let’s talk insulin — because this is where the rhetoric meets results.
For years, Americans suffering from diabetes were getting hammered. Not nicked. Hammered. Life-saving insulin — a drug discovered over a century ago — became a profit center for the vertically integrated healthcare machine who treated patients like ATMs.
Prices skyrocketed. Families rationed doses. Seniors cut pills in half. Working-class Americans had to choose between groceries and staying alive.
That wasn’t a market. That was a shakedown.
Enter Trump 2.0
His Rx initiative didn’t come with a press tour or a Hollywood rollout. It came with pressure. Behind closed doors and in public. He put the system on notice: the days of Big Insurance Pharmacy Benefit Managers (PBMs) middleman markups and Americans subsidizing foreign countries’ prescription drugs were coming to an end.
PBMs are the unelected middlemen sitting between drug companies, insurers, and you. They don’t make the drugs, they don’t take the meds — they just skim profits, manipulate pricing, and drive up costs behind closed doors.
Then Trump did something Washington almost never does — he backed it up.
Enter TrumpRx.gov, stage right.
By tying negotiating directly with drug manufacturers, cutting out the middleman PBMs, and introducing transparency into a system built on smoke and mirrors, Trump flipped the script. Suddenly, the leverage shifted. Drug prices dropped for the American patient.
And insulin? That’s the headline.
We’re seeing prices that used to run hundreds of dollars per month drop dramatically — in many cases to capped levels around $35, and even lower in certain programs, approaching single-digit monthly costs for some patients depending on coverage and provider agreements.
Read that again.
From hundreds… to tens… and in some cases, near single digits.
That’s not incremental change. That’s life-changing.
That’s the difference between compliance and crisis. Between stability and an ER visit. Between dignity and desperation.
And it’s not just insulin.
Across the board, we’re seeing better deals on key medications — from blood pressure drugs to treatments for chronic conditions that used to drain bank accounts. Big Insurance PBMs — the shadow operators who jacked up prices behind the scenes — are finally being dragged into the light.
This didn’t happen because of a think tank white paper. It didn’t happen because of a bipartisan commission that met for three years and produced a PDF no one read.
It happened because Trump treated the problem like what it is: a broken system rigged against the American people.
He used the power of the presidency the way a CEO uses leverage — negotiate hard, demand results, and don’t blink.
And here’s what really sticks in the craw of the establishment: it worked.
Americans are paying less. Access is improving. And the fear that used to come with a pharmacy visit is starting to ease for millions.
Of course, the critics will say it’s not enough. They’ll move the goalposts. They always do. But ask a family now paying $35 instead of $500 a month if it matters.
Ask a senior on a fixed income if it matters.
Ask someone who no longer has to ration insulin if it matters.
This is what results look like.
No slogans. No gimmicks. No empty promises.
Just lower prices and real relief.
That’s TrumpRx.
And that’s changing lives.